Antithrombotic Therapy for Medically Managed STEMI
Christopher P. Cannon, MD (Chair)
Harvard Medical School | Boston, MA

Antiplatelet Therapy in Clinical Practice: Balancing the Risks and Benefits
Deepak L. Bhatt, MD, FACC, FSCAI, FAHA
VA Boston Healthcare System | Boston, MA

How to Apply New Anticoagulant Data to Clinical Practice
E. Magnus Ohman, MD, FRCPI, FACC
Duke University Medical Center | Durham, NC

Maximizing Patient Outcomes and Compliance: Protecting Post-ACS Patients at Risk for Thromboembolic Complications
Joanne Foody, MD
Brigham and Women's Faulkner Hospitals| Boston, MA

James J. Ferguson, III, MD
Associate Director, Clinical Cardiology Research, The Texas Heart Institute at St. Luke’s Episcopal Hospital
Associate Professor of Medicine, Baylor College of Medicine
Clinical Assistant Professor, The University of Texas Health Science Center at Houston

Patients With Prior Myocardial Infarction, Stroke, or
Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
Deepak L. Bhatt, Marcus D. Flather, Werner Hacke, et al
Reprinted with permission from J Am Coll Cardiol. 2007;49:1982-1988.

Impact of Platelet Reactivity After Clopidogrel
Administration on Drug-Eluting Stent Thrombosis
Piergiovanni Buonamici, Rossella Marcucci, Angela Migliorini, et al
Reprinted with permission from J Am Coll Cardiol. 2007;49:2312-2317.

Variability in Individual Responsiveness to Clopidogrel:
Clinical Implications, Management, and Future Perspectives
Dominick J. Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al
Reprinted with permission from J Am Coll Cardiol. 2007;49:1505-1516.